ABCG1 Promoter — A Tagging Variant in the Cholesterol Efflux Locus
ABCG1 (ATP-binding cassette transporter G1 | a membrane protein that pumps
cholesterol from macrophages and other peripheral cells onto HDL particles
in the bloodstream) is one of
two key transporters that drive reverse cholesterol transport — the pathway
that clears excess cholesterol from arterial walls and returns it to the
liver for disposal. rs2234714 sits in an intronic region of the ABCG1 gene
approximately 768 base pairs upstream of a transcribed region, tagging the
same chromosomal segment as other ABCG1 promoter variants that have been
linked to coronary artery disease (CAD) susceptibility.
The variant does not appear to alter ABCG1 transcription directly — a
luciferase reporter assay found no functional effect from this specific
position. Its CAD association is therefore most likely due to linkage
disequilibrium | the non-random co-inheritance of nearby alleles, so that
rs2234714 tracks alongside a functionally important nearby variant without
itself causing the effect with functionally relevant variants at the
ABCG1 promoter locus, particularly rs57137919 (-367G>A).
The Mechanism
ABCG1 acts as the second-wave transporter in the two-step cholesterol
efflux relay. ABCA1 | ATP-binding cassette transporter A1, which
initiates reverse cholesterol transport by loading nascent HDL
particles starts the process
by attaching cholesterol and phospholipids to lipid-poor apolipoprotein A-I.
ABCG1 then continues the relay, pumping additional cholesterol onto these
maturing HDL particles and enabling them to carry larger cholesterol loads
back to the liver.
A functional study of the nearby rs57137919 promoter variant | Liu et al.
ABCG1 rs57137919G>A polymorphism is functionally associated with varying gene
expression and apoptosis of macrophages. PLoS One, 2014
demonstrated that reduced ABCG1 expression at this locus causes approximately
23% less cholesterol efflux to HDL in macrophages and a 2-fold increase in
apoptosis of cholesterol-loaded macrophages — hallmarks of impaired plaque
clearance. While rs2234714 did not show the same functional signal in reporter
assays, it resides on the same genomic segment and tracks alongside this
biologically meaningful variation.
Beyond lipid transport, ABCG1 also suppresses the NLRP3 inflammasome |
Westerterp et al. Cholesterol Efflux Pathways Suppress Inflammasome
Activation, NETosis, and Atherogenesis. Circulation, 2018
in macrophages and monocytes. When cholesterol efflux is impaired, intracellular
cholesterol accumulation triggers inflammatory cytokine release (IL-1β, IL-18)
independently of circulating HDL-C — meaning ABCG1 variants can raise
cardiovascular risk through inflammation, not just through lipid channels.
The Evidence
The primary association study | Xu et al. A polymorphism in the ABCG1 promoter
is functionally associated with coronary artery disease in a Chinese Han population.
Atherosclerosis, 2011 enrolled 1,021
CAD patients and 1,013 controls from a Han Chinese cohort. The rs2234714 A allele
was associated with reduced CAD risk in a recessive model (adjusted OR 0.64,
p = 0.015), meaning AA homozygotes had approximately 36% lower odds of CAD
compared to G-allele carriers. Importantly, the authors found no functional
effect of this specific variant in promoter reporter assays, suggesting the
association is driven by LD with the functionally active rs57137919 variant
rather than by rs2234714 itself.
The evidence is currently limited to this single study in one population.
No large European GWAS or replication cohort has independently confirmed the
rs2234714 CAD signal. This places the evidence at the emerging level until
replicated in independent populations.
A comprehensive pharmacological review | Frambach et al. Brothers in Arms:
ABCA1- and ABCG1-Mediated Cholesterol Efflux as Promising Targets in
Cardiovascular Disease Treatment. Pharmacol Rev, 2020
reinforces the broader biological relevance of the ABCG1 locus: reduced
transporter expression is rate-limiting for reverse cholesterol transport,
and pharmacological enhancement of ABCG1 activity is an active therapeutic
research direction for atherosclerosis prevention.
Practical Actions
Because rs2234714 is likely a tagging variant, its most actionable implication
is that G-allele homozygotes may carry a slightly higher burden of risk variants
at the ABCG1 promoter locus. Supporting ABCG1-mediated cholesterol efflux
through dietary and lifestyle approaches has the same mechanistic rationale
here as for other ABCG1 variants. Omega-3 fatty acids (EPA/DHA) upregulate
ABCG1 expression in macrophages through PPAR-gamma and LXR signaling pathways.
Monitoring HDL-C as a surrogate for reverse cholesterol transport efficiency
is warranted for GG homozygotes.
Interactions
rs2234714 lies on the same ABCG1 haplotype block as rs1044317 (3'UTR regulatory
variant) and rs57137919 (promoter variant with documented functional effects on
expression and macrophage cholesterol efflux). Individuals carrying risk haplotypes
spanning multiple ABCG1 variants may have greater cumulative impairment of
cholesterol efflux than any single variant predicts. ABCA1 variants (rs2853579,
rs4149268) affect the first step of the same cholesterol efflux relay, and
compound effects across the ABCA1–ABCG1 pathway are biologically plausible.
Alla genotyper
Common ABCG1 genotype — baseline reverse cholesterol transport
You carry two copies of the G allele at rs2234714, the most common genotype globally (~44% of people). In the Chinese Han study, GG carriers formed the reference group against which A-allele carriers were compared. Your ABCG1 function at this locus is not expected to be altered by this specific variant. The broader ABCG1 pathway function is determined by other variants on your haplotype.
Two copies of the A allele — associated with lower CAD risk in one population study
You carry two copies of the A allele at rs2234714. This is the least common genotype globally (~11% of people). In the Chinese Han case-control study of 1,021 CAD patients and 1,013 controls, AA homozygotes had approximately 36% lower odds of coronary artery disease compared to G-allele carriers (adjusted OR 0.64, p = 0.015, recessive model). The protective association was not accompanied by any functional effect at this specific position, suggesting rs2234714 acts as a tagging variant for a nearby functional change. The evidence is from a single study in one population and has not been replicated independently. The finding is encouraging but should be held provisionally until confirmed in broader cohorts.
One copy of the A allele — modest trend toward lower CAD risk
You carry one copy of the A allele and one copy of the G allele at rs2234714. About 45% of people globally share this AG genotype, making it the most common genotype. Based on the published association study, the protective signal in the recessive model is strongest for AA homozygotes; heterozygotes do not show a statistically significant reduction in CAD risk. Your risk profile from this variant is therefore intermediate — slightly different from GG but without confirmed benefit. The evidence for this variant is from a single Chinese Han population study; replication in other populations is lacking. Interpret with appropriate caution.